Most biotech analysts have been concentrating heavily on the weakened flow of venture dollars into the industry. But if you look at the licensing side of the business, you'll also find some solid reasons for concern.
It takes money to make money and yet another pharmaceutical maker is partnering in a venture capital fund, this one designed to draw drug companies to Quebec.
A venture group backed by the Russian government and tasked with building a drug development industry in the country is partnering with Quintiles to go to work on the clinical trial end of the...
Australia's Vaxxas has garnered about $16.46 million in venture capital financing to support development of its Nanopatch delivery technology, which the company says could drastically change how
Liquidia Technologies has garnered the final piece of a $25 million Series C, which will fund development of a new vaccine delivery technology. The clinical research organization PPD invested $5
Genocea Biosciences' work in vaccine discovery has won over a lineup of venture capital groups which are investing $23 million in the developer. The money is earmarked for five development programs,
Bozeman, MT-based LigoCyte Pharmaceuticals has rounded up $28 million in its third round of venture capital. The money will be used for the clinical development of two lead vaccines targeting
The venture capital group Perseus has pumped $10 million dollars into NanoBio, bringing its total investment in the University of Michigan spin-off to $30 million. The developer has been working on